| COVANCE ELECTS DR. ROBERT BARCHI TO BOARD OF DIRECTORS |
 |
Princeton, New Jersey, August 25, 2003 — Covance Inc. (NYSE: CVD) today announced that it has elected Robert Barchi, M.D., Ph.D., Provost of the University of Pennsylvania, to its Board of Directors, effective October 1, 2003.
Dr. Barchi has extensive experience in the management of complex institutions and in medical research and pharmaceutical development. He has been Provost of the University of Pennsylvania, one of the nation's most prestigious universities with more than 22,500 students and 4,800 faculty members, since 1999. Previously, he served as Chair of Penn's Department of Neurology and as founding Chair of the University's Department of Neuroscience. Dr. Barchi was also Director of the Mahoney Institute of Neurological Sciences for more than 12 years and was the Director of the Dana Fellowship Program in Neuroscience and Director of the Clinical Neuroscience Track. He was the founder and President of Penn Neurocare, a regional specialty network. Dr. Barchi is the author of more than 150 publications in his fields of neurology and neuroscience.
Dr. Barchi is a graduate of Georgetown University and earned his Ph.D. and M.D. from the University of Pennsylvania. He completed a residency at the Hospital of the University of Pennsylvania and is board certified in the specialty of neurology, an area in which he continues his clinical practice. He is a member of the Institute of Medicine of the National Academy of Sciences, and has received numerous awards for his outstanding work in the sciences.
"I am pleased to welcome Bob Barchi to the Covance Board of Directors. His experience of managing large and diverse academic and scientific institutions as well as his decades of dedication towards medical advancements will strengthen Covance and our ability to help our biopharmaceutical clients bring the miracles of modern medicine to market sooner," said Chris Kuebler, Covance Chairman and Chief Executive Officer.
Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with 2002 net revenues of $883 million, global operations in 18 countries, and approximately 6,800 employees worldwide. Information on Covance's products and services, recent press releases, and SEC filings can be obtained through the website in the About Covance area. |
|
|
